PCI Pharma Services to acquire Ajinomoto Althea from Ajinomoto.

PCI Pharma Services, a contract development and manufacturing organization, agreed to acquire Ajinomoto Althea, a sterile fill-finish CDMO, from Ajinomoto, a multinational food and biotechnology corporation. Financial terms were not disclosed. “To continue supporting the needs of our customers in their endeavors to bring life-changing therapies to patients, PCI continues to make sizable investments in the sterile fill-finish category that bring additional capabilities, capacity and technologies into our portfolio. Welcoming Althea into the PCI family expands our capabilities to support several therapeutic and drug delivery modalities, including the emerging ADC marketplace, and complements our broad end-to-end solutions alongside clinical trial services and advanced drug delivery," Salim Haffar, PCI Pharma Services CEO.